Cardiology clinics
-
Considerable progress has been made over the past decade in understanding the etiology, prevalence, natural history, and therapeutic approach to chronic thromboembolic pulmonary hypertension. Pulmonary endarterectomy is now widely recognized as the definitive treatment for chronic pulmonary hypertension resulting from thromboembolic disease. This article focuses on the surgical treatment of chronic thromboembolic pulmonary hypertension.
-
During the past 2 decades, there has been a steady rise in the number of patients with chronic thromboembolic pulmonary hypertension (CTEPH) undergoing surgery and in the number of programs worldwide dedicated to the diagnosis and management of this patient population. This article discusses the natural history and clinical presentation of CTEPH, the evaluation of patients for pulmonary thromboendarterectomy, and the outcomes following surgery, along with a brief review of the procedure as performed at the University of California, San Diego.
-
To control ventricular rate in patients with AF, physicians should seek to control heart rate at rest and with exertion. The goal has to be achieved while minimizing costs and adverse effects. For emergency use, i.v. diltiazem or esmolol are drugs useful because of their rapid onset of action. ⋯ Adequate ventricular rate control by pharmacological agents should be evaluated by either 24-hour Holter monitoring or a submaximal stress test to determine the resting and exercise ventricular rate. If the mean ventricular rate is not close to 80 beats per minute, or the heart rate on moderate exertion is not between 90 to 115 beats per minute, a second agent to control the rate should be added. Excessive reductions in ventricular rates that could limit exercise tolerance should be avoided.
-
The CardioWest TAH was created and initially tested at the same time as the Thoratec, Novacor, and HeartMate devices. It was designed as a permanent artificial heart and was the first-ever mechanical circulatory device to be used as destination therapy. Twenty years have passed since that early experience. ⋯ Pneumatic technology has improved with portability and miniaturization, and there is reason to believe that it will become even better. Application of modern manufacturing techniques to this very simple device raises the possibility of significant manufacturing cost reduction, in an era of prohibitive cost for other devices. All of this establishes the CardioWest as a valuable device for any program that is seriously interested in end-stage heart disease and a likely device for permanent use in appropriately selected patients.
-
As the role of the LVAD graduates from the "bridge-to-transplant" to the "bridge-to-recovery," several important issues need to be answered. Such a paradigm would require a definition of appropriate candidates for LVAD implantation, the most appropriate time for LVAD placement during the management of end-stage CHF, reliable histologic, biochemical, and imaging markers of recovery, and the optimum duration of LVAD support. ⋯ It will be a challenge to identify the role for concomitant drug therapy and to develop weaning programs for device support. Finally, guidelines will have to be developed to monitor and manage these patients after explantation of LVAD.